Eupraxia Pharmaceuticals (EPRX) to Release Earnings on Tuesday

Eupraxia Pharmaceuticals (NASDAQ:EPRX) is expected to be announcing its results before the market opens on Tuesday, March 31st. Analysts expect the company to announce earnings of ($0.13) per share for the quarter.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last issued its quarterly earnings data on Thursday, March 19th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.21). On average, analysts expect Eupraxia Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Eupraxia Pharmaceuticals Stock Up 3.2%

Eupraxia Pharmaceuticals stock opened at $7.33 on Tuesday. The stock has a 50-day simple moving average of $8.24 and a 200 day simple moving average of $6.93. The stock has a market capitalization of $263.59 million, a price-to-earnings ratio of -7.12 and a beta of 1.27. Eupraxia Pharmaceuticals has a 12-month low of $2.68 and a 12-month high of $9.32.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. Vivo Capital LLC bought a new stake in Eupraxia Pharmaceuticals in the 3rd quarter valued at $7,965,000. Ikarian Capital LLC bought a new position in shares of Eupraxia Pharmaceuticals in the fourth quarter valued at about $4,606,000. Squadron Capital Management LLC bought a new position in shares of Eupraxia Pharmaceuticals in the fourth quarter valued at about $3,775,000. Velan Capital Investment Management LP acquired a new stake in shares of Eupraxia Pharmaceuticals during the 3rd quarter worth about $2,077,000. Finally, Royal Bank of Canada boosted its holdings in shares of Eupraxia Pharmaceuticals by 21.1% during the 1st quarter. Royal Bank of Canada now owns 342,828 shares of the company’s stock worth $1,125,000 after buying an additional 59,683 shares during the period.

Analyst Ratings Changes

A number of brokerages have weighed in on EPRX. Lifesci Capital raised shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, December 11th. Wall Street Zen cut shares of Eupraxia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, February 21st. HC Wainwright lowered their price target on shares of Eupraxia Pharmaceuticals from $12.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, March 17th. Zacks Research cut shares of Eupraxia Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 17th. Finally, Cantor Fitzgerald upped their price objective on Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the stock an “overweight” rating in a report on Thursday, January 15th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.